Medizinische Universität Graz - Research portal

Logo MUG Resarch Portal




Terbuch, A; Walser, G; Stotz, M; Gerger, A; Posch, F; Bauernhofer, T Primary Thromboprophylaxis and the Risk of Venous Thromboembolic Events in Patients With Testicular Germ Cell Tumors Treated With Cisplatinum-Based Chemotherapy.
Clin Genitourin Cancer. 2023; 21(1):24-31 Doi: 10.1016/j.clgc.2022.10.005
Web of Science PubMed FullText FullText_MUG



Alijotas-Reig, J; Esteve-Valverde, E; Ferrer-Oliveras, R; Sáez-Comet, L; Lefkou, E; Mekinian, A; Belizna, C; Ruffatti, A; Tincani, A; Pardos-Gea, J; Nalli, C; Marozio, L; Espinosa, G; De, Carolis, S; Latino, O; Sebastian, U; LLurba, E; Trespidi, L; Chighizola, C; Pengo, V; Rovere-Querini, P; Canti, V; Mayer-Pickel, K; Reshetnyak, T; Tabacco, S; Arnau, A Bleeding and antithrombotic therapy during pregnancy in women with poor aPL-related obstetric outcomes: A survey of 1075 cases from EUROAPS registry∗.
Eur J Anaesthesiol. 2021; 38(9): 916-922. Doi: 10.1097/EJA.0000000000001484
Web of Science PubMed FullText FullText_MUG



Posch, F; Königsbrügge, O; Zielinski, C; Pabinger, I; Ay, C Treatment of venous thromboembolism in patients with cancer: A network meta-analysis comparing efficacy and safety of anticoagulants.
Thromb Res. 2015; 136(3):582-589 Doi: 10.1016/j.thromres.2015.07.011 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG



Gary, T Cancer related venous thromboembolism - prophylaxis and therapy.
Vasa. 2014; 43(4):245-251 Doi: 10.1024/0301-1526/a000359
Web of Science PubMed FullText FullText_MUG



Watzke, H; Metzler, H; Weltermann, A; Marschang, P; Brodmann, M; Lang, W; Pabinger-Fasching, I; Mahla, E; Kozek-Langenecker, S; Guschmann, M; Huber, K Periprocedual management of vitamin K antagonist's with low molecular weight heparins during invasive procedures--Consensus of experts].
Wien Klin Wochenschr. 2013; 125(13-14):412-420 Doi: 10.1007/s00508-013-0390-7
Web of Science PubMed FullText FullText_MUG



Schenk, P; Rosenkranz, AR; Wolfl, G; Horl, WH; Traindl, O Recombinant tissue plasminogen activator is a useful alternative to heparin in priming quinton permcath.
Am J Kidney Dis. 2000; 35(1):130-136 Doi: 10.1016/S0272-6386(00)70311-8
Web of Science PubMed FullText FullText_MUG


Szolar-Platzer, C; Aberer, W; Kränke, B Delayed-type skin reaction to the heparin-alternative danaparoid.
J Am Acad Dermatol. 2000; 43(5 Pt 2):920-922 Doi: 10.1067%2Fmjd.2000.101875 (- Case Report)
Web of Science PubMed FullText FullText_MUG Google Scholar


© Med Uni GrazImprint